Pfizer Inc. (PFE)
PFE Gets FDA Nod for Expanded Use of RSV Vaccine Abrysvo
The FDA approves Pfizer's RSV vaccine, Abrysvo, for adults aged 18-59 years with increased risk of the disease.
Should You Buy, Sell or Hold Pfizer Stock Before Q3 Earnings?
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.
The Best Pharmaceutical Stock to Invest $1,000 in Right Now
Its cheap valuation, strong growth prospects, and massive dividend make it ripe for outsize investment returns.
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
Is Pfizer's Attractive Valuation Enough to Invest in the Stock?
PFE's non-COVID drugs and potential contributions from new and newly acquired products have started to drive growth.
Activist Investor Starboard Slams Pfizer for Underperforming R&D And Overpaying for Acquisitions
Activist investor Starboard Value has sharpened its criticism of Pfizer Inc. PFE, holding the pharmaceutical giant's management accountable for failing to deliver on its promises of innovation and growth.
Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises
Starboard took aim at Pfizer in another blow Tuesday, saying the company has failed to deliver on what it called the "best pipeline" ever.
Activist hedge fund Starboard met with Pfizer last week. Here's what went down.
Activist hedge fund Starboard has taken a stake in drug giant Pfizer. Starboard execs met with company officials last week to outline their complaints.
Pfizer (PFE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Starboard Value CEO Jeff Smith: Pfizer needs to do a better job disciplining itself on investments
Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential for growth in Kenvue, and more.
Do Billionaires Israel Englander and Ken Griffin Know Something? Each Just Bought This Plagued Value Stock.
Hedge funds managed by Israel Englander and Ken Griffin both scooped up shares in a troubled pharmaceutical stock last quarter.
Starboard Makes Its Case to Shake-Up Pfizer and Kenvue
Starboard has a $1 billion stake in Pfizer and an unknown but "sizable" stake in Kenvue, according to earlier media reports.
